GlassScriptPhysician profile
Philip Leipprandt
NPI 1528217890
$8,926.25
in general payments reported to CMS, 2019-2025
43 companies · $2,267 in 2025
The $2,267 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $429 · 2021: $819 · 2022: $1,094 · 2023: $1,288 · 2024: $1,627 · 2025: $2,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,099 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,098.54 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,310.78 | 2019-2025 | |
| Janssen Biotech, INC. | $1,345.91 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $767.61 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Daiichi Sankyo INC. | $413.12 | 2019-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $344.93 | 2019-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $337.33 | 2019-2025 | Xifaxan |
| Covidien LP | $309.89 | 2019 | |
| Intercept Pharmaceuticals, INC. | $269.44 | 2019-2025 | Ocaliva |
| Allergan, INC. | $256.22 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $247.72 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $245.88 | 2022-2025 | Dupixent |
| Boston Scientific Corporation | $200.24 | 2019-2025 | Watchman Access System, Autotome Rx 49, Spyglass Discover |
| Lilly USA, LLC | $182.86 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $152.68 | 2024-2025 | Ibsrela |
| Urogen Pharma, INC. | $149.97 | 2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $138.75 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $132.80 | 2024-2025 | |
| Endo USA, INC. | $127.57 | 2024-2025 | Xiaflex |
| Madrigal Pharmaceuticals | $109.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $104.14 | 2021-2025 | |
| Medtronic, INC. | $101.30 | 2021-2024 | Endoflip |
| Janssen Pharmaceuticals, INC | $91.97 | 2019 | |
| Genzyme Corporation | $89.94 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $89.59 | 2019 | |
| Evoke Pharma, INC. | $67.65 | 2023 | Gimoti |
| Ucb, INC. | $44.53 | 2019 | |
| Organogenesis INC. | $30.25 | 2025 | Puraply Wound Matrix |
| Leica Microsystems INC. | $27.02 | 2025 | Neoprobe |
| Edwards Lifesciences Corporation | $23.36 | 2020 | |
| Glaxosmithkline, LLC. | $20.61 | 2020 | |
| Baxter Healthcare | $17.66 | 2025 | Perclot |
| Calyxo, INC. | $16.85 | 2025 | Cvac Aspiration System |
| Redhill Biopharma INC. | $16.24 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.54 | 2024 | |
| Endo Pharmaceuticals INC. | $15.31 | 2023 | Xiaflex |
| Sumitomo Pharma America, INC. | $15.15 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $15.03 | 2023 | |
| Erbe USA INC | $15.00 | 2025 | Vio300d |
| Solventum Corporation | $14.56 | 2025 | V.A.C. Veraflo, V.A.C.Ulta, Prevena |
| Olympus America INC. | $13.60 | 2025 | Endoclot Phs |
| Convatec INC. | $13.38 | 2019 | |
| Csl Behring | $13.11 | 2019 | |
| Vivus LLC | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Leipprandt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.